Companies › Clinuvel
1 active drug program in 1 registered trial: 1 Phase 3; Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Afamelanotide Melanocortin receptor 1 agonist | MC1R | Phase 3 | Vitiligo | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06109649 | Afamelanotide | Phase 3 | Vitiligo | Immunology | Dec 2025 |
Cash and short-term investments of $174m on 2026-06-30; operating cash flow positive
Bioventus ALK-Abelló Kolon TissueGene Doron Therapeutics UnicoCell Biomed
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.